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Zika virus genome biology and molecular pathogenesis
Anyou Wang1*, Stephanie Thurmond2,*, Leonel Islas1,2, Kingyung Hui2 and Rong Hai1,2
Zika virus (ZIKV) is an emerging RNA virus in the widespread Flavivirus genus. Recently, ZIKV has rapidly spread around the
world and has been implicated in human disease, including neurological disorders, triggering public and scientific attention.
Understanding how ZIKV causes disease is the highest priority, yet little is known about this virus. Here we examine the
currently published data from ZIKV studies to provide the latest understanding of ZIKV genome biology and molecular
pathogenesis. The ZIKV genome evolved rapidly from the Flavivirus genus and diverged from the members of this genus, even
within the dengue virus cluster to which ZIKV belongs. Genome variations and divergences also exist among ZIKV strains/
isolates. These genome divergences might account for the uniqueness of Zika disease. ZIKV infection activates not only the
antiviral immune response but also the pro-inflammatory responses associated with disease symptoms. Strikingly, ZIKV activates
protein complexes that are functionally associated with disease process, such as glial cell activation and proliferation (for
example, Toll-like receptors), apoptosis and cell death, and inflammation. The activation of these complexes may critically
contribute to Zika disease. The novel insights into ZIKV genome divergence and disease mechanisms summarized in this review
will help accelerate the development of anti-ZIKV strategies.
Emerging Microbes & Infections (2017) 6, e13; doi:10.1038/emi.2016.141; published online 22 March 2017
INTRODUCTION
Zika virus (ZIKV) is a single-stranded positive-sense RNA arbovirus
belonging to the Flavivirus genus of the Flaviviridae family, members
of which cause widespread morbidity worldwide.1 Since the recent
large outbreak in 2007, ZIKV has rapidly spread throughout South
America, Central America and the Caribbean, and has been implicated
in neurological disorders such as microcephaly, a condition in which
the fetal brain does not properly develop.2,3 ZIKV has also been linked
to Guillain–Barré syndrome (GBS), an autoimmune disease that
causes paralysis.4 The severity of the diseases associated with Zika
and its rapid spread have triggered an urgent need to understand
this virus.
ZIKV was first isolated in 1947 from a sentinel rhesus monkey in
Uganda.5 In 1952, it was found in humans, and it was linked to Zika
disease in 1964.6 However, little attention was paid to this virus until
2007, when an outbreak of ‘dengue-like illness’ was reported in the
Yap State of Micronesia. It was estimated that 470% of Yap State
residents were infected with ZIKV.7 Another outbreak occurred in
2013 in French Polynesia and subsequently in other Pacific Islands.8
Outbreaks also occurred in New Caledonia, the Cook Islands and
Easter Island,9 and ZIKV circulation has been reported in other Pacific
islands. To date, the ZIKV outbreak in Brazil is the largest ever
recorded, with an estimated 165 000 suspected and confirmed cases as
of August 2016.10
This rapid spread of ZIKV and its implication in severe disease have
prompted the scientific community to develop interventions to
combat Zika disease. However, the disease mechanism is not currently
understood. Here we review and analyze emerging studies of ZIKV
genome biology and pathogenesis to provide insight into ZIKV
molecular pathogenesis to facilitate the development of Zika disease
prevention strategies. However, this review does not provide a general
overview of ZIKV; such overviews have recently been published.2,11–16
ZIKV GENOME BIOLOGY
The entire genome of the African prototype ZIKV strain (MR 766)
was sequenced for the first time in 2007, and epidemic ZIKV strains
are currently being sequenced at a rapid pace. The ZIKV genome
comprises a 10.8-kb single-stranded positive-sense RNA molecule that
contains an ~ 100 nt 5′ untranslated region (UTR), a single open
reading frame of ~ 10 kb, and an ~420 nt 3′ UTR.17 The open reading
frame encodes a single polyprotein, which is later processed into the
capsid (C); the precursor membrane (prM); the envelope protein (E);
and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B and NS5; Figure 1A). We next discuss the ZIKV genome, its
divergence from other Flavivirus members, and the genetic variations
found among various ZIKV isolates.
Genome evolution
Flavivirus genus members have evolved rapidly and divergently. To
understand the evolutionary relatedness of ZIKV to other members of
the Flavivirus genus, we performed a phylogenetic analysis using the
genome sequences of representative Flavivirus members (Figure 1B).
The analysis confirmed that ZIKV clusters with dengue viruses
(DENVs) at a higher hierarchical level; however, ZIKV is most closely
related to Spondweni virus, resulting in an individual ZIKV cluster in
the phylogenetic tree. This separation of the ZIKV cluster from other
clusters at a similar hierarchical level (for example, DENV and West
Nile virus (WNV)) suggested that ZIKV may have evolved disease
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mechanisms distinct from these other viruses despite the similarity in
disease symptoms exhibited by dengue, West Nile and ZIKV-infected
individuals (Figure 1B).
Another unique characteristic of ZIKV is its high homologous
recombination activity. ZIKV appears to have undergone multiple
recombination events between 1947 and 2007. Such active recombina-
tion is uncommon among flaviviruses and has been suggested as a
mechanism for the adaptation of ZIKV to the Aedes dalzieli vector.18
Strains and isolates within the ZIKV species have also evolved
rapidly. These strains can be clustered into two major lineages: African
and Asian (Figure 1C). Some investigators further divide the African
lineages into West African and East African lineages.18–20 Many of
the African lineage ZIKV strains were isolated from mosquitoes
(Figure 1C). The Asian lineage evolved from the Malaysia/1966 isolate.
The Asian strains, which originated from the 2013 French Polynesian
strain, are responsible for the recent epidemics, whereas the Brazilian
isolates are most closely related to the 2014 Haitian strain (Figure 1C).
The Yap State and Philippines epidemic strains originated from the
same common ancestor, but the French Polynesian strain was not as
closely related to the Yap isolate as originally reported (Figure 1C).8 Of
note, a small subset of the strains included in our analysis were
passaged in the laboratory prior to sequencing, and this passaging
could have introduced sequence divergences. However, although
passaging and other factors might contribute to divergence individu-
ally, the overall pattern presented here is likely not affected given that
most of the strains are natural isolates that have not been passaged.
The genomic variation in geographically distinct ZIKV isolates
accounts for the above evolutionary patterns. A total of 75 amino-acid
substitutions were identified in the African lineage compared with the
epidemic Asian lineage, and a total of 34 amino-acid changes and
more than 400 nt variations are noted in the Asian lineage compared
with the original Malaysia/1966 strain. However, the overall genome
sequences are highly similar (488.9%). The recent epidemic strains
from Brazil harbor 14–18 nt variations compared with the other
human strains in the same lineage. The most highly variable region in
both the Asian and African lineages is the pr region of the prM
protein, with ~ 10% amino-acid variation.21
In addition, genetic divergences exist in strains isolated from
infected individuals. Strains isolated from fetuses with microcephaly
(ZIKV2015, Natal RGN and BeH823339) carry specific mutations.
ZIKV2015 harbors amino-acid mutations at polyprotein positions 550,
1143, 1259 and 2831. Natal RGN contains mutations at positions 940,
1027 and 2509, whereas BeH823339 is mutated at 7 positions
(337, 354, 358, 545, 984, 1404 and 2800).22 However, no mutations
Figure 1 ZIKV genome divergence. (A) The ZIKV genome. (B) The ZIKV genome diverges from Flavivirus members. A phylogenetic tree was constructed
using all gap-free sites from whole-genome sequences aligned by MAFFT (http://mafft.cbrc.jp/alignment/software/) using a bootstrap of 1000 and neighbor
joining. The same method was applied to C. (C) ZIKV strain evolution based on geographic area. Zika virus, ZIKA.
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were found that were common to all three isolates. Thus, further
studies are needed to clarify the connection between these mutations
and microcephaly.
Genetic differences were also found in the UTRs of the epidemic
strains compared with the pre-epidemic prototype strain. Specifically,
a large 9-nt bulge (UAG UCA GCC) replaces the 3′ UTR stem-loop
region in epidemic ZIKV.23 Variations in UTRs may have an impact
on viral genome stability, replicative efficiency and, consequently,
overall viral fitness and transmissibility. Further experimentation is
required to determine whether differential functions are associated
with genome sequence variations.
Phylogenetic studies have exposed patterns of ZIKV genome
evolution and variations, but these patterns are based on limited
ZIKV isolate availability. With more strain sequences becoming
available, the origins of ZIKV and its evolutionary pattern should
become clearer. When combined with other factors, such as geography
and clinical data, the global ZIKV migration pattern and ZIKV
genome evolution will be elucidated.
Functional genomics
The genomes of all members in the Flavivirus genus share certain
common properties, and the functional genomics of ZIKV has mostly
been inferred from previous work with other flaviviruses. These
viruses encode the same proteins in the same order flanked by a 5′
and 3′ UTR. The 5′ UTR contains the vRNA promoter and terminates
with a type I cap, followed by the conserved dinucleotide AG. The 3′
end of the transcript is not polyadenylated and is instead terminated
with a conserved CUOH.
24
The C protein comprises the viral capsid, which is icosahedral in
shape and surrounded by a spherical lipid bilayer membrane derived
from the host. The M and E proteins are displayed on the viral surface
and have transmembrane helices that anchor them in the outer
membrane. As mature viral particles egress, the prM protein is cleaved
by a furin-like protease located in the trans-Golgi network into the pr
peptide and the M protein. It has been hypothesized that prior to this
step, the prM protein participates in E protein folding.25
The E protein is the major virion surface protein and is involved in
host cell binding and membrane fusion. The structure of the ZIKV E
protein in complex with the flavivirus broadly neutralizing antibody
2A10G6 was also solved, and this antibody was shown to neutralize
ZIKV infection in vitro and protect mice in vivo.26
The structure of the E protein exposed a potentially important
difference between ZIKV and other flaviviruses. DENV is glycosylated
at Asn67 on the E protein, which is important for binding to the host
receptor DC-SIGN.27 ZIKV apparently lacks this glycosylation site but
is glycosylated at Asn154 in many of the strains that have been
analyzed. The DENV E protein is also glycosylated at the same
location (Asn153), and this modification is beneficial for virion
release.28 Similarly, the glycosylation of the WNV E protein enhances
the virus’ neurotropic virulence.29 The region surrounding this
glycosylated area tends to vary among flaviviruses and may be an
important determinant for antibody specificity.
The nonstructural proteins (NS1-NS5) form the replicative complex
and play a role in host innate immunity antagonism. The ZIKV NS1
protein is highly similar to other flaviviruses, with a noted divergent
electrostatic potential on the loop surface. This divergent region is
involved in binding host factors and protective antibodies, so it could
be a potential antiviral target. The NS1 protein has also been
implicated in immune evasion and appears to play a role in viral
replication along with NS4A.30 NS2A, NS2B, NS4A and NS4B are
hydrophobic proteins that may be membrane-associated. However,
they do not have any known enzymatic motifs, and their specific
functions have yet to be elucidated.23 The NS3 protein is central to
viral replication and polyprotein processing due to its N-terminal
protease domain along with its C-terminal RNA helicase activity. The
NS5 protein has two known activities: an RNA-dependent RNA
polymerase activity performed by the C terminus and an RNA capping
function executed by the methyltransferase domain located at the N
terminus.18 NS5 suppresses IFN signaling via proteasome-dependent
degradation of human STAT2.31
MOLECULAR PATHOGENESIS
Transmission
Similar to many other flaviviruses, ZIKV is mainly transmitted by a
mosquito bite, and the skin is the first line of defense against infection.
To date, Zika vRNA has been isolated from seven different Aedes
species. Unlike many flaviviruses, however, there is strong evidence to
indicate that ZIKV can be transmitted from human to human through
many different routes, including sexual contact, blood transfusion and
vertically from mother to fetus.32 Indeed, Zika vRNA persists in semen
longer than in blood, saliva or urine. In one case study, Zika vRNA
was detected in a patient’s semen sample for up to 6 months after the
onset of illness.33 Similarly, vRNA has been detected in the female
genital tract, and a suspected case of female-to-male transmission has
been reported.34 Although ZIKV RNA persists in urine and saliva, it is
not yet known whether these fluids can facilitate transmission.
ZIKV-associated diseases
Infection with ZIKV is often asymptomatic but can cause mild
symptoms similar to those of dengue fever, except the breaking bone
pain. During the 2013 French Polynesia outbreak, an increase in
reported GBS was reported.35 This report marked the first time Zika
was associated with severe neurological complications. There have also
been reports of other Zika-associated neurological diseases.36,37
There have also been more children with microcephaly and other
congenital abnormalities born to ZIKV-infected women in Northeast
Brazil.38,39 During the French Polynesia outbreak, there were
more cases of central nervous system malformations concurrent
with the ZIKV epidemic.35 The Centers for Disease Control and
Prevention therefore declared that prenatal Zika virus infection
causes microcephaly; however, definitive causality remains to be
established.40,41
The increase in microcephaly cases in Brazil temporally associated
with the recent ZIKV epidemic has driven researchers to establish
causality between ZIKV and congenital neurological complications.
Zika vRNA has been detected in fetal brain tissues.42 A ZIKV strain of
African lineage, MR766, preferentially infected neural progenitor cells
(NPCs) in 14-day-old forebrain organoids and caused a reduction in
organoid size. In 28-day-old organoids, which contain progenitor cells
in addition to NPCs, most ZIKV-infected cells were NPCs, indicating
specific tropism. These brains exhibited reduced ventricular zones and
neuronal layer thicknesses, resembling microcephaly.43
Disease mechanisms
Consistent with mosquito bite transmission, ZIKV infects human
dermal fibroblasts, epidermal keratinocytes and immature dendritic
cells.44 The congenital abnormalities associated with ZIKV suggest that
it may also be capable of bypassing the placental barrier, and in vitro
evidence demonstrates that ZIKV is able to infect human placental
macrophages and cytotrophoblasts.45 Animal model experiments have
also demonstrated ZIKV infection of the placenta and fetal brain,
resulting in diminished brain development.42,46–48 No other flavivirus
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has definitively been shown to cause birth defects in humans,
suggesting that this tropism may be specific to ZIKV. Consistent with
ZIKV causing neurological disorders, ZIKV can also infect human
NPCs, neurospheres and forebrain organoids.43,49–51
To understand the mechanism of Zika disease, we constructed a
systems network based on the currently available data47,50 (Figure 2A).
Genes (nodes) in this network are activated by ZIKV infection and
interact with each other to generate a host immune response. For
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Figure 2 Immune response to ZIKV. (A) An immune response network was constructed using published RNA-seq data. The network was inferred from the
systems network database as we previously described,52 including domains, co-localization, physical interaction and co-expression. Briefly, the protein–protein
interactions were extracted from a database and subsequently enriched for significant genes derived from RNA-seq data, as described in our publication.52
The color of a node (gene) denotes the expression level; expression increases from light red to dark red when compared with mock controls. A line (linkage)
represents the interaction type, yellow—common protein domain, blue—co-localization, green—physical interaction. For illustration, the other interactions are
labeled as white as background. (B) A proposed scheme of the inflammation initiated by ZIKV infection leading to an antiviral response and an inflammatory
response associated with diseases. Zika virus, ZIKV.
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illustrative proposes, we regrouped this entire network into three
subnetworks: virus entry, antiviral response and pro-inflammatory
complexes associated with disease development (Figures 2A and 2B).
ZIKV penetrates host cells via receptor-mediated endocytosis.
Current evidence suggests that the cell-surface phosphatidylserine
receptor Axl functions as the primary receptor for ZIKV entry.44,48
The viral E proteins, which are arranged as dimers on the viral surface,
mediate attachment to the host cell. Viral entry and replication trigger
the host immune response (Figures 2A and 2B).
These immune responses could also function as antiviral and pro-
inflammatory responses. The antiviral response primarily includes
three modules (protein complexes): cell surface receptors (Fcer1g,
Ptprc, Ptpn6, Syk and C3ar1); the innate immune response (Fcgr1,
Irgm1, Ptpn6, Cd180, Sp110, Ddx58, Mx2, Mx1, Samhd1, Ifih1,
Rnf135, Dhx58 and Trim25); and plasma proteins associated with the
acute inflammatory response (C4b, C1qb, C1qa, Serping1, Masp1,C2
and C1qc; Figure 2A). These antiviral immune responses may also
cause inflammation, leading to disease symptoms.
ZIKV also activates inflammatory modules (Figure 2A), including
factors involved in the inflammatory response (Ccl12, Nfkbiz,
Tnfrsf1b, Cxcl10, Ccl7, Ccl5, Ccl3 and Ccl2), the adaptive immune
response (Serpinb9, Icam1 and Relb), B-cell-mediated immunity
(Inpp5d, Irf7 and Icosl), the regulation of T-cell-mediated immunity
(B2m and Tap2), antigen presentation (Tapbpl, Psmb8, Psmb9,
Psme2 and Psme1), leukocyte-mediated immunity (Ncf1) and the
regulation of cytokine production (Irf8, Irf1, Ptgs2, Elf1 and Tspo).
Activating these inflammatory response modules could attract T cells
and other leukocytes to the site of infection. In addition, they may
enhance cytokine and chemokine production. Ultimately, the accu-
mulation of these immune factors leads to tissue damage. Consistent
with the strong inflammatory response, it has been hypothesized that
ZIKV infection can cause autoimmune diseases, such as GBS.35
Interestingly, ZIKV also activates modules associated with apoptosis
and glial cell regulation (Figure 2A); these modules include microglial
cell activation (Tlr3, Tlr7 and Tlr9), regulation of glial cell prolifera-
tion (Lyn and Tspo), positive regulation of apoptosis (Stat1, Eif2ak2,
Ifi204, Shisa5, Pml, Casp7, Casp4 and Tnfsf10), and regulation of
programmed cell death (Kdr, Adar, Herpud1, Spp1, Kat2a, Pde3a and
Atf5). The activation of these modules is consistent with reports
demonstrating that ZIKV infection induces cell apoptosis and death,
and dysregulates cell cycle progression.44,47,49–51
To summarize the network modules and pathways potentially
involved in the diseases initiated by ZIKV, we proposed a scheme to
model ZIKV molecular pathogenesis (Figure 2B). ZIKV entry and
replication together activate signaling pathways such as Toll-like
receptor pathways, which subsequently activate transcription factors.
These transcription factors cause dysregulation of host cell transcrip-
tion, leading to antiviral and pro-inflammatory responses, apoptosis
and dysregulation of glial cell proliferation. This proposed model may
help to elucidate the molecular mechanism behind ZIKV-induced
microcephaly, in which pro-inflammatory and apoptotic pathways in
pregnant mice are activated, and the size of the developing forebrain is
markedly reduced.43
These network modules were computationally inferred from a
systems network database as previously described52 and should be
validated by further experimental data. However, many of these
module components have been observed in recent reports, and most
of them, such as apoptosis,53 are shared by other flavivirus members,
but some are unique to ZIKV, such as the cell-surface receptor Axl.44
Although the network pattern helps us to understand the disease
mechanism of ZIKV, it is limited by a small available data set and
resource bias given that a considerable amount of the data were
generated using immunodeficient mice. This network should be built
upon and further validated by including new emerging data.
Protection against ZIKV
Larocca et al. developed two conventional vaccine platforms, a DNA
vaccine and a purified inactivated virus vaccine. Both vaccines were
tested for efficacy in mice. Six different DNA vaccine candidates were
designed, each with different frameshift mutations. The prM-Env-
expressing plasmid, which was derived from the Brazil P ZIKV
BeH815744 strain, elicited higher Env-specific antibody titers than
the other DNA candidates and provided the most protection against
homologous ZIKV infection. The immunologic mechanism of protec-
tion against ZIKV challenge was due to Env-specific IgG and was
T-cell-independent. The inactivated virus vaccine also provided
complete protection against viral challenge in the mouse model.
However, the protective efficacy of this platform varied with the
mouse strain, suggesting host-specific responses to viral infection. This
varied host response warrants further investigation in human hosts,
but extension of these vaccine platforms to human application is
promising.54
ZIKV-specific antibodies are another potential therapeutic means to
combat ZIKV infection. However, special care should be taken when
evaluating such antibodies to avoid antibody-dependent enhancement
(ADE) in individuals previously infected with DENV. ADE is a
phenomenon in which non-neutralizing antibodies facilitate hetero-
logous virus entry into host cells, and it was recently demonstrated
that DENV antibodies can drive ADE of ZIKV infection.55 One study
found that antibodies against the ZIKV E protein domain I/II (EDI/II)
are cross-reactive to DENV and are poorly neutralizing. These
antibodies also enhance both ZIKV and DENV infection. By contrast,
EDIII-specific antibodies are potent ZIKV-specific neutralizing anti-
bodies, and one EDIII-specific antibody protected mice from lethal
ZIKV infection.56 This study serves as a proof of principle for
antibody-based therapy and provides a template for the development
of potent neutralizing ZIKV antibodies.
CHALLENGES AND FUTURE DIRECTIONS
ZIKV has rapidly spread around the world. However, given that Zika
disease symptoms resemble those of other arboviral diseases and that
ZIKV infection is often mild or asymptomatic, its prevalence is likely
underestimated. However, overestimation of ZIKV prevalence can also
occur. Serological and molecular tests frequently produce false-positive
results due to cross-reactivity and sequence similarities with other
flaviviruses.57 Because of these complications, future studies should
combine conventional clinical data with mathematical modeling and
computational biology concepts to dissect the complexity of Zika
disease.
In the past, Flavivirus disease models have relied on immunodefi-
cient mice because many flaviviruses are not able to efficiently
antagonize the mouse innate immune response, preventing viral
replication. ZIKV researchers have encountered a similar problem.
In addition, Zika disease severity varies with the genetic background of
each mouse strain. This variation leads to the challenge of generating
consistent results from ZIKV-infected mouse models. This problem is
compounded when applying discoveries from mouse models to
humans due to non-trivial differences in mouse and human biology.
Future studies should address these differences and work to develop an
authentic mechanism of ZIKV mammalian pathogenesis.
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CONCLUSION
The rapid evolution of the ZIKV genome accounts for the recent
ZIKV pandemic and the uniqueness of Zika disease. The immune
network is activated by ZIKV and functions in glial cell activation and
proliferation, apoptosis and cell death. The promotion of inflamma-
tion critically contributes to Zika diseases. The novel molecular
insights of ZIKV pathogenesis provided here will help to combat Zika
diseases and eventually eliminate ZIKV.
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